Effects of cannabinoid CB1 receptor agonism and antagonism on SKF81297-induced dyskinesia and haloperidol-induced dystonia in Cebus apella monkeys.
Madsen
Morten V
MV
Research Institute of Biological Psychiatry, Sct. Hans Hospital, Denmark.
Peacock
Linda P
LP
Werge
Thomas
T
Andersen
Maibritt B
MB
Andreasen
Jesper T
JT
D000818:Animals; D001552:Benzazepines / Q000633:toxicity*; D002428:Cebus; D003511:Cyclohexanols / Q000494:pharmacology / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000503:physiopathology; D004421:Dystonia / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D006220:Haloperidol / Q000633:toxicity*; D008297:Male; D010880:Piperidines / Q000494:pharmacology / Q000627:therapeutic use; D011720:Pyrazoles / Q000494:pharmacology / Q000627:therapeutic use; D043884:Receptor, Cannabinoid, CB1 / Q000819:agonists* / Q000037:antagonists & inhibitors* / Q000502:physiology; D000077285:Rimonabant
D001552:Benzazepines; D003511:Cyclohexanols; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; C067113:SK&F 81297; C054649:3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol; D006220:Haloperidol; D000077285:Rimonabant